Panellists supported NHS-commissioned services that enable men at risk of prostate cancer to access PSA testing outside of primary care, although several panellists raised concerns regarding ‘screening by the back door’ associated with such initiatives. This evidence concerns the gene KLK3 and prostate cancer.